United States Pre-Market Tobacco Application Pharmacokinetics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

67 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-19

Study Completion Date

2018-11-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Randomized, Open-Label, Cross-Over Study to Assess Nicotine Uptake and Subjective Measures with Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) Compared to Usual Brand Combustible Cigarettes, a Comparator E-Cigarette, and Nicotine Gum in Healthy Adult Smokers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers

NCT03593239

Nicotine Dependence Nicotine Dependence, Cigarettes Tobacco Use +1 more

COMPLETED NA

Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems

NCT04123041

Electronic Cigarette Use Tobacco Smoking

COMPLETED NA

Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers

NCT03463837

Nicotine Dependence, Other Tobacco Product Tobacco Use Smoking, Tobacco

COMPLETED NA

Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS

NCT04107779

Electronic Cigarette Use Cigarette Use, Electronic Tobacco Use +1 more

COMPLETED NA

Clinical Study Comparing 7 ENDS Products and 1 Combustible Cigarette Using 2 Delivery Methods.

NCT03700112

Nicotine Dependence Nicotine Dependence, Cigarettes Tobacco Use +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

E-cigarettes may be an acceptable alternative to traditional cigarette smoking. In utilizing vaporization rather than combustion, the generation and inhaltion of smoke and carbon monoxide (CO) may be reduced or avoided. JUUL has developed several nicotine based liquid blends for use in e-cigarettes. This study will assess nicotine uptake during a 10-puff controlled and a 5-minute ad libitum use of four JUUL 5% electronic nicotine delivery systems (ENDS) relative to usual brand (UB) combustible cigarettes, a comparator electronic cigarette (e-cigarette), and nicotine gum.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nicotine Dependence Nicotine Dependence, Cigarettes Tobacco Use Tobacco Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, Open-Label, Cross-Over

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

JUUL 5% Virginia Tobacco ENDS

Treatment with JUUL Virginia Tobacco flavored 5.0% ENDS product.

Group Type EXPERIMENTAL

Virginia Tobacco flavored JUUL 5% ENDS

Intervention Type OTHER

Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).

JUUL 5% Cool Mint ENDS

Treatment with JUUL Cool Mint flavored 5.0% ENDS product.

Group Type EXPERIMENTAL

Cool Mint flavored JUUL 5% ENDS

Intervention Type OTHER

Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).

JUUL 5% Mango ENDS

Treatment with JUUL Mango flavored 5.0% ENDS product.

Group Type EXPERIMENTAL

Mango flavored JUUL 5% ENDS

Intervention Type OTHER

Treatment with Mango flavored JUUL 5% ENDS (10 puffs).

JUUL 5% Creme Brulee ENDS

Treatment with JUUL Creme Brulee flavored 5.0% ENDS product.

Group Type EXPERIMENTAL

Creme Brulee flavored JUUL 5% ENDS

Intervention Type OTHER

Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).

VUSE Solo e-cigarette

Treatment with VUSE Solo Original with 4.8% nicotine product.

Group Type ACTIVE_COMPARATOR

VUSE Solo e-cigarette

Intervention Type OTHER

Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).

Nicotine Gum

Treatment with nicorette white ice mint 4mg nicotine polacrilex gum product.

Group Type ACTIVE_COMPARATOR

Nicorette White Ice Mint 4mg nicotine polacrilex gum

Intervention Type OTHER

Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)

Usual Brand Combustible Cigarette

Treatment with usual brand combustible cigarette.

Group Type ACTIVE_COMPARATOR

Usual Brand combustible cigarette

Intervention Type OTHER

Treatment with usual brand cigarette (10 puffs).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Virginia Tobacco flavored JUUL 5% ENDS

Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).

Intervention Type OTHER

Cool Mint flavored JUUL 5% ENDS

Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).

Intervention Type OTHER

Mango flavored JUUL 5% ENDS

Treatment with Mango flavored JUUL 5% ENDS (10 puffs).

Intervention Type OTHER

Creme Brulee flavored JUUL 5% ENDS

Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).

Intervention Type OTHER

VUSE Solo e-cigarette

Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).

Intervention Type OTHER

Nicorette White Ice Mint 4mg nicotine polacrilex gum

Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)

Intervention Type OTHER

Usual Brand combustible cigarette

Treatment with usual brand cigarette (10 puffs).

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

JUUL JUUL JUUL JUUL VUSE Nicotine Gum

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, adult, male or female smoker, 21 to 65 years of age, inclusive
* Has been a smoker for at least 12 months prior to Screening. Brief periods of non-smoking (e.g., up to \~7 consecutive days due to illness, trying to quit, participation in a study where smoking was prohibited) during that time will be permitted at the discretion of the PI.
* Currently smokes an average of 10 or more king size or 100s manufactured combustible CPD, as reported at Screening.
* Has a positive urine cotinine (≥ 500 ng/mL) at Screening
* Has an exhaled CO \> 12 ppm at Screening.
* Is willing to comply with the requirements of the study, including a willingness to use the study products during the study.

Exclusion Criteria

* Has a history or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the PI, would jeopardize the safety of the subject or impact the validity of the study results.
* Has a clinically significant abnormal finding on the physical examination, medical history, vital signs, ECG, or clinical laboratory results, in the opinion of the PI.
* Has a positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at Screening.
* Has had an acute illness (e.g., upper respiratory infection, viral infection) requiring treatment within 14 days prior to Check-in.
* Has a fever (\> 100.5°F) at Screening or Check-in.
* Has a body mass index (BMI) \> 40.0 kg/m2 or \< 18.0 kg/m2 at Screening.
* Has a history of drug or alcohol abuse within 24 months of Check-in, as determined by the PI.
* Has diabetes mellitus, asthma, or chronic obstructive pulmonary disease.
* Has a systolic blood pressure \< 90 mmHg or \> 150 mmHg, diastolic blood pressure \< 40 mmHg or \> 95 mmHg, or heart rate \< 40 bpm or \> 99 bpm at Screening.
* Has experienced an allergic reaction following previous e-cigarette use or with exposure to any primary components of the e-liquids (benzoic acid, propylene glycol and glycerol).
* Has an estimated creatinine clearance \< 80 mL/minute (using the Cockcroft-Gault equation) at Screening.
* Has a positive urine screen for alcohol or drugs of abuse at Screening or Check-in.
* Has used medications known to interact with cytochrome P450 (CYP) 2A6 (including, but not limited to, amiodarone, amlodipine, amobarbital, buprenorphine, clofibrate, clotrimazole, desipramine, disulfiram, entacapone, fenofibrate, isoniazid, ketoconazole, letrozole, methimazole, methoxsalen, metyrapone, miconazole, modafinil, orphenadrine, pentobarbital, phenobarbital, pilocarpine, primidone, propoxyphene, quinidine, rifampicin, rifampin, secobarbital, selegiline, sulconazole, tioconazole, tranylcypromine) within 14 days or 5 half-lives of the drug, whichever is longer, prior to Check-in.
* Has used nicotine-containing products other than manufactured cigarettes (e.g., ENDS, roll-your-own cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) within 14 days prior to Check-in.
* Has a prior history of JUUL product use prior to Screening
* Has used any prescription smoking cessation treatments, including, but not limited to, varenicline (Chantix®) or buproprion (Zyban®) within 3 months prior to Check-in.
* Is a self-reported puffer (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale).
* Is planning to quit smoking during the study or postponing a quit attempt in order to participate in the study.
* Has donated plasma within 7 days prior to Check-in.
* Has donated blood or blood products (with the exception of plasma as noted above), had significant blood loss, or received whole blood or a blood product transfusion within 56 days prior to Check-in.
* Has participated in a previous clinical study for an investigational drug, device, biologic, or tobacco product within 30 days prior to Check-in.
* Is or has a first-degree relative (i.e., parent, sibling, child) who is a current employee of the study site.
* Is or has a first-degree relative (i.e., parent, sibling, child) who is a current employee, shareholder, or is member of the board of directors of JUUL Labs Inc.
* Has previously been diagnosed with any form of cancer, except for basal cell or squamous epithelial carcinomas of the skin that have been resected at least 1 year prior to Screening.

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes